{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:28:34Z","timestamp":1791260914808,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2007,5,1]],"date-time":"2007-05-01T00:00:00Z","timestamp":1177977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2007,5]]},"DOI":"10.1053\/j.gastro.2007.02.037","type":"journal-article","created":{"date-parts":[[2007,2,22]],"date-time":"2007-02-22T09:42:55Z","timestamp":1172137375000},"page":"1767-1777","source":"Crossref","is-referenced-by-count":532,"title":["Dynamic Hepatitis C Virus Genotypic and Phenotypic Changes in Patients Treated With the Protease Inhibitor Telaprevir"],"prefix":"10.1053","volume":"132","author":[{"given":"Christoph","family":"Sarrazin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara L.","family":"Kieffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doug","family":"Bartels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Hanzelka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ute","family":"M\u00fch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Welker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Wincheringer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui\u2013May","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Weegink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk","family":"Reesink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Zeuzem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann D.","family":"Kwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2007.02.037_bib1","series-title":"What\u2019s in the pipeline: new HIV drugs, vaccines, microbicides, HCV and TB treatments in clinical trials","article-title":"The hepatitis C virus (HCV) treatment pipeline","author":"Swan","year":"2005"},{"key":"10.1053\/j.gastro.2007.02.037_bib2","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1002\/hep.1840360706","article-title":"Natural history of chronic hepatitis C","volume":"36","author":"Seeff","year":"2002","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2007.02.037_bib3","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1097\/01.TP.0000140927.63952.58","article-title":"Hepatitis B and hepatitis C viruses in liver transplantation","volume":"78","author":"Curry","year":"2004","journal-title":"Transplantation"},{"key":"10.1053\/j.gastro.2007.02.037_bib4","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1574-6976.1994.tb00087.x","article-title":"Hepatitis C virus: historical perspective and current concepts","volume":"14","author":"Purcell","year":"1994","journal-title":"FEMS Microbiol Rev"},{"key":"10.1053\/j.gastro.2007.02.037_bib5","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1002\/hep.20119","article-title":"Diagnosis, management, and treatment of hepatitis C","volume":"39","author":"Strader","year":"2004","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2007.02.037_bib6","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2007.02.037_bib7","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2007.02.037_bib8","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","article-title":"Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose","volume":"140","author":"Hadziyannis","year":"2004","journal-title":"Ann Intern Med"},{"issue":"Suppl 2","key":"10.1053\/j.gastro.2007.02.037_bib9","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1055\/s-2004-832934","article-title":"Past, present, and future hepatitis C treatments","volume":"24","author":"Foster","year":"2004","journal-title":"Semin Liver Dis"},{"key":"10.1053\/j.gastro.2007.02.037_bib10","first-page":"35","article-title":"Global surveillance and control of hepatitis C\u2014report of the WHO consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium","volume":"6","author":"Organization","year":"1999","journal-title":"J Viral Hepat"},{"key":"10.1053\/j.gastro.2007.02.037_bib11","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM199811193392101","article-title":"Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C","volume":"339","author":"McHutchison","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2007.02.037_bib12","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/S0140-6736(98)07124-4","article-title":"Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus","volume":"352","author":"Poynard","year":"1998","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2007.02.037_bib13","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1093\/jac\/dki405","article-title":"Treating HCV with ribavirin analogues and ribavirin-like molecules","volume":"57","author":"Gish","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1053\/j.gastro.2007.02.037_bib14","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/hep.20065","article-title":"Hepatitis C","volume":"39","author":"Pawlotsky","year":"2004","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2007.02.037_bib15","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jhep.2005.12.001","article-title":"The face of future hepatitis C antiviral drug development: recent biological and virologic advances and their translation to drug development and clinical practice","volume":"44","author":"McHutchison","year":"2006","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2007.02.037_bib16","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/nature02099","article-title":"An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus","volume":"426","author":"Lamarre","year":"2003","journal-title":"Nature"},{"key":"10.1053\/j.gastro.2007.02.037_bib17","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1053\/j.gastro.2004.08.002","article-title":"Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients","volume":"127","author":"Hinrichsen","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2007.02.037_bib18","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/hep.20612","article-title":"Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C","volume":"41","author":"Reiser","year":"2005","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2007.02.037_bib19","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2007.01.041","article-title":"SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon \u03b1-2b for genotype 1 non-responders","author":"Sarrazin","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2007.02.037_bib20","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1128\/AAC.50.3.899-909.2006","article-title":"Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease","volume":"50","author":"Perni","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.gastro.2007.02.037_bib21","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1053\/j.gastro.2006.07.013","article-title":"Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study","volume":"131","author":"Reesink","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2007.02.037_bib22","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1128\/AAC.48.6.2260-2266.2004","article-title":"Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro","volume":"48","author":"Lu","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.gastro.2007.02.037_bib23","doi-asserted-by":"crossref","first-page":"17508","DOI":"10.1074\/jbc.M313020200","article-title":"In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms","volume":"279","author":"Lin","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1053\/j.gastro.2007.02.037_bib24","doi-asserted-by":"crossref","first-page":"8205","DOI":"10.1074\/jbc.M510246200","article-title":"Mutations conferring resistance to SCH6, a novel hepatitis C virus NS3\/4A protease inhibitor","volume":"281","author":"Yi","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1053\/j.gastro.2007.02.037_bib25","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1128\/JVI.77.6.3669-3679.2003","article-title":"In vitro selection and characterization of hepatitis C virus serine protease variants resistant to an active-site peptide inhibitor","volume":"77","author":"Trozzi","year":"2003","journal-title":"J Virol"},{"key":"10.1053\/j.gastro.2007.02.037_bib26","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1128\/JCM.44.3.729-737.2006","article-title":"Comparison of conventional PCR with real-time PCR and branched DNA-based assays for hepatitis C virus RNA quantification and clinical significance for genotypes 1 to 5","volume":"44","author":"Sarrazin","year":"2006","journal-title":"J Clin Microbiol"},{"key":"10.1053\/j.gastro.2007.02.037_bib27","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1002\/hep.20819","article-title":"Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes","volume":"42","author":"Simmonds","year":"2005","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2007.02.037_bib28","doi-asserted-by":"crossref","first-page":"783","DOI":"10.2307\/2408678","article-title":"Confidence limits on phylogenies: an approach using the bootstrap","volume":"39","author":"Felsenstein","year":"1985","journal-title":"Evolution"},{"key":"10.1053\/j.gastro.2007.02.037_bib29","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1006\/viro.2001.1092","article-title":"Quasispecies heterogeneity of the carboxy-terminal part of the E2 gene including the PePHD and sensitivity of hepatitis C virus 1b isolates to antiviral therapy","volume":"289","author":"Sarrazin","year":"2001","journal-title":"Virology"},{"key":"10.1053\/j.gastro.2007.02.037_bib30","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0378-1119(98)00020-1","article-title":"Spontaneous cAMP-dependent derepression of gene expression in stationary phase plays a role in recombinant expression instability","volume":"209","author":"Grossman","year":"1998","journal-title":"Gene"},{"key":"10.1053\/j.gastro.2007.02.037_bib31","doi-asserted-by":"crossref","first-page":"36784","DOI":"10.1074\/jbc.M506462200","article-title":"In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061","volume":"280","author":"Lin","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1053\/j.gastro.2007.02.037_bib32","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.antiviral.2006.03.004","article-title":"Antiviral drug resistance","volume":"71","author":"Richman","year":"2006","journal-title":"Antiviral Res"},{"key":"10.1053\/j.gastro.2007.02.037_bib33","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1128\/CMR.15.2.247-277.2002","article-title":"Genotypic testing for human immunodeficiency virus type 1 drug resistance","volume":"15","author":"Shafer","year":"2002","journal-title":"Clin Microbiol Rev"},{"key":"10.1053\/j.gastro.2007.02.037_bib34","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMra025195","article-title":"HIV drug resistance","volume":"350","author":"Clavel","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2007.02.037_bib35","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.antiviral.2005.12.003","article-title":"Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034","volume":"70","author":"Tong","year":"2006","journal-title":"Antiviral Res"},{"key":"10.1053\/j.gastro.2007.02.037_bib36","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.1128\/JVI.78.8.4234-4247.2004","article-title":"Role of minority populations of human immunodeficiency virus type 1 in the evolution of viral resistance to protease inhibitors","volume":"78","author":"Charpentier","year":"2004","journal-title":"J Virol"},{"key":"10.1053\/j.gastro.2007.02.037_bib37","first-page":"96","article-title":"Scientific rationale for antiretroviral therapy in 2005: viral reservoirs and resistance evolution","volume":"13","author":"Siliciano","year":"2005","journal-title":"Top HIV Med"},{"key":"10.1053\/j.gastro.2007.02.037_bib38","doi-asserted-by":"crossref","DOI":"10.1002\/hep.21774","article-title":"Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C","author":"Forestier","year":"2007","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2007.02.037_bib39","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1053\/j.gastro.2006.06.100","article-title":"28 Days of the hepatitis C protease inhibitor VX-950, in combination with peg-interferon-alfa-2a (Pegasys) and ribavirin, is well-tolerated and demonstrates robust antiviral effects","volume":"131","author":"Lawitz","year":"2006","journal-title":"Gastroenterology"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508507003940?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508507003940?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,8]],"date-time":"2019-01-08T23:59:45Z","timestamp":1546991985000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508507003940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,5]]}},"alternative-id":["S0016508507003940"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2007.02.037","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2007,5]]}}}